Preclinical (145 companies)
Companies with at least one active program at Preclinical.
| Ticker | Company | Therapeutic areas | Preclinical programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| FDMT | 4D Molecular Therapeutics | OphthalmologyRespiratory Rare | 2 | Phase 3 | $608M | 5 |
| AARD | Aardvark Therapeutics | DermatologyMetabolic+1 Rare | 1 | Phase 3 | $25.2M | 3 |
| ABSI | Absci | DermatologyGI/Hepatology+1 | 3 | Phase 1 | $1.31B | 6 |
| ACRS | Aclaris Therapeutics | DermatologyGI/Hepatology+1 Rare | 1 | Phase 2 | $536M | 7 |
| ACRV | Acrivon Therapeutics | GI/HepatologyOncology Rare | 2 | Phase 2 | $61.4M | 9 |
| ACTU | Actuate Therapeutics | Oncology | 1 | Phase 2 | $15.2M | 4 |
| ABOS | Acumen Pharmaceuticals | Neurology | 2 | Phase 2 | $16.6M | 4 |
| ADAG | Adagene | Oncology | 3 | Phase 2 | $99.4M | 10 |
| ADCT | ADC Therapeutics | Oncology | 1 | Approved | $172M | 5 |
| ACET | Adicet Bio | ImmunologyNeurology+2 Rare | 1 | Phase 1 | $26.0M | 8 |
| ADMA | Adma Biologics | ImmunologyInfectious Disease Rare | 1 | Approved | $3.02B | 4 |
| AGMB | Agomab Therapeutics | ImmunologyRespiratory Rare | 2 | Phase 2 | $292M | 4 |
| AKBA | Akebia Therapeutics | HematologyOphthalmology+2 Rare | 2 | Approved | $111M | 10 |
| ALDX | Aldeyra Therapeutics | DermatologyOncology+1 | 1 | NDA Submitted | $41.9M | 5 |
| ATHE | Alterity Therapeutics | Neurology Rare | 1 | Phase 2 | $35.7M | 2 |
| AMLX | Amylyx Pharmaceuticals | MetabolicNeurology Rare | 1 | Phase 3 | $3.54B | 5 |
| ANTX | AN2 Therapeutics | HematologyInfectious Disease+1 Rare | 2 | Phase 2 | $161M | 6 |
| ANIX | Anixa Biosciences | Oncology | 1 | Phase 1 | $92.8M | 3 |
| APGE | Apogee Therapeutics | DermatologyGI/Hepatology+1 Rare | 2 | Phase 2 | — | 9 |
| APVO | Aptevo Therapeutics | Oncology | 6 | Phase 1 | $1.6M | 8 |
| RCUS | Arcus Biosciences | DermatologyImmunology+1 | 2 | Phase 3 | $2.36B | 8 |
| ARDX | Ardelyx | GI/HepatologyRenal | 1 | Approved | $799M | 4 |
| AVBP | ArriVent BioPharma | Oncology | 2 | Phase 3 | $553M | 7 |
| ARVN | Arvinas | NeurologyOncology Rare | 1 | Approved | $447M | 10 |
| ATAI | Atai Beckley | Neurology | 2 | Phase 2 | $2.73B | 5 |
| AXSM | Axsome Therapeutics | Neurology Rare | 2 | Approved | $7.15B | 15 |
| BLTE | Belite Bio | MetabolicOphthalmology Rare | 4 | NDA Submitted | $6.35B | 6 |
| BCYC | Bicycle Therapeutics | Oncology | 1 | Phase 2 | $224M | 4 |
| BDTX | Black Diamond Therapeutics | Oncology | 1 | Phase 2 | $82.8M | 4 |
| BCTX | BriaCell Therapeutics | Oncology | 6 | Phase 3 | $30.7M | 8 |
| CADL | Candel Therapeutics | Oncology | 1 | Phase 3 | $424M | 4 |
| CRDL | Cardiol Therapeutics | Cardiovascular Rare | 1 | Phase 3 | $124M | 4 |
| CLRB | Cellectar Biosciences | Oncology | 1 | Phase 2 | $9.2M | 7 |
| IPSC | Century Therapeutics | ImmunologyMetabolic+1 Rare | 5 | Phase 1 | $249M | 9 |
| COGT | Cogent Biosciences | HematologyOncology Rare | 2 | NDA Submitted | $4.85B | 7 |
| CRVS | Corvus Pharmaceuticals | DermatologyOncology+1 Rare | 1 | Phase 3 | $858M | 7 |
| COYA | Coya Therapeutics | Neurology Rare | 4 | Phase 2 | $70.8M | 6 |
| CUE | Cue Biopharma | ImmunologyOncology | 2 | Phase 2 | $23.7M | 6 |
| CGEM | Cullinan Therapeutics | HematologyImmunology+2 Rare | 2 | NDA Submitted | $602M | 10 |
| CTMX | CytomX Therapeutics | Oncology | 1 | Phase 1 | $423M | 7 |
| IRON | Disc Medicine | GI/HepatologyHematology+2 Rare | 1 | Phase 3 | $3.49B | 9 |
| DYN | Dyne Therapeutics | MetabolicNeurology Rare | 8 | NDA Submitted | $3.00B | 10 |
| EIKN | Eikon Therapeutics | Oncology | 1 | Phase 2 | $279M | 13 |
| ELTX | Elicio Therapeutics | Oncology | 3 | Phase 2 | $40.5M | 6 |
| ENTA | Enanta Pharmaceuticals | DermatologyImmunology+2 | 2 | Approved | $253M | 8 |
| ENTX | Entera Bio | GI/HepatologyMetabolic Rare | 2 | Phase 2 | $522M | 4 |
| ERAS | Erasca | Oncology | 1 | Phase 1 | $4.87B | 5 |
| ETON | Eton Pharmaceuticals | GI/HepatologyInfectious Disease+3 Rare | 1 | Approved | $1.84B | 17 |
| EVMN | Evommune | DermatologyImmunology+1 | 2 | Phase 2 | $290M | 6 |
| EXEL | Exelixis | CardiovascularOncology | 3 | Approved | $16.7B | 23 |
| EYPT | EyePoint | Ophthalmology | 1 | Phase 3 | $34.1M | 2 |
| FATE | Fate Therapeutics | ImmunologyOncology+1 Rare | 3 | Phase 2 | $124M | 10 |
| FHTX | Foghorn Therapeutics | Oncology | 3 | Preclinical | $110M | 4 |
| FBIO | Fortress Biotech | DermatologyHematology+4 Rare | 3 | Approved | $61.4M | 16 |
| GANX | Gain Therapeutics | MetabolicNeurology Rare | 4 | Phase 1 | $52.5M | 5 |
| HRMY | Harmony Biosciences | MetabolicNeurology Rare | 6 | Approved | $1.94B | 17 |
| HROW | Harrow | Ophthalmology Rare | 2 | Approved | $1.11B | 15 |
| IDYA | IDEAYA Biosciences | Oncology | 1 | NDA Submitted | $2.65B | 15 |
| IMUX | Immunic | GI/HepatologyNeurology | 1 | Phase 3 | $116M | 4 |
| IMCR | Immunocore | DermatologyInfectious Disease+2 | 1 | Approved | $1.44B | 12 |
| IMNM | Immunome | Oncology Rare | 2 | NDA Submitted | $2.03B | 9 |
| INAB | IN8bio | ImmunologyOncology | 1 | Phase 1 | $8.9M | 4 |
| INBX | Inhibrx Biosciences | Oncology | 1 | NDA Submitted | $1.10B | 6 |
| IVVD | Invivyd | Infectious Disease | 2 | Approved | $152M | 5 |
| JBIO | Jade Biosciences | ImmunologyRenal Rare | 2 | Phase 2 | $1.07B | 4 |
| KAPA | Kairos Pharma | Oncology | 7 | Phase 2 | $1.9M | 12 |
| KZIA | Kazia Therapeutics | NeurologyOncology Rare | 5 | Phase 2 | $60.7M | 13 |
| KROS | Keros Therapeutics | NeurologyOncology Rare | 1 | Phase 3 | $222M | 5 |
| KOD | Kodiak Sciences | Ophthalmology | 2 | Phase 3 | $6.33B | 8 |
| KURA | Kura Oncology | MetabolicOncology | 4 | Approved | $688M | 13 |
| KYMR | Kymera Therapeutics | DermatologyImmunology+1 Rare | 1 | Phase 2 | $10.4B | 5 |
| KYTX | Kyverna Therapeutics | ImmunologyNeurology+1 Rare | 1 | NDA Submitted | $297M | 6 |
| LXEO | Lexeo Therapeutics | CardiovascularNeurology Rare | 7 | Phase 2 | $236M | 12 |
| LCTX | Lineage Cell Therapeutics | MetabolicNeurology+1 Rare | 10 | Phase 2 | $207M | 13 |
| LGVN | Longeveron | CardiovascularNeurology Rare | 1 | Phase 2 | $7.1M | 3 |
| MAIA | MAIA Biotechnology | Oncology | 6 | Phase 3 | $77.2M | 8 |
| MRKR | Marker Therapeutics | Oncology | 1 | Phase 1 | $14.0M | 5 |
| MBX | MBX Biosciences | Metabolic Rare | 2 | Phase 3 | $2.64B | 4 |
| MDNAF | Medicenna Therapeutics | Oncology | 7 | Phase 2 | $14.8M | 10 |
| MGTX | MeiraGTx | ImmunologyMetabolic+2 Rare | 7 | Phase 3 | $827M | 16 |
| INKT | MiNK Therapeutics | ImmunologyOncology+1 Rare | 3 | Phase 2 | $47.7M | 8 |
| MBRX | Moleculin Biotech | Oncology | 4 | Phase 2 | $7.3M | 9 |
| GLUE | Monte Rosa Therapeutics | CardiovascularDermatology+3 Rare | 1 | Phase 2 | $775M | 7 |
| NKTR | Nektar Therapeutics | DermatologyImmunology+2 | 4 | Phase 3 | $1.23B | 11 |
| NGEN | NervGen Pharma | Neurology | 2 | Phase 3 | $211M | 3 |
| NRSN | NeuroSense Therapeutics | Neurology Rare | 1 | Phase 2 | $2.9M | 3 |
| NRXP | NRX Pharmaceuticals | Neurology Rare | 4 | Approved | $109M | 11 |
| NRIX | Nurix Therapeutics | ImmunologyNeurology+1 | 1 | Phase 3 | $1.56B | 13 |
| OCGN | Ocugen | Infectious DiseaseOphthalmology Rare | 3 | Phase 3 | $257M | 12 |
| OCS | Oculis Holding | NeurologyOphthalmology Rare | 2 | Phase 3 | $418M | 5 |
| OMER | Omeros | HematologyNeurology+2 Rare | 2 | Approved | $1.04B | 6 |
| ONCY | Oncolytics Biotech | Oncology | 1 | Phase 2 | $51.7M | 4 |
| OKUR | OnKure Therapeutics | Oncology | 2 | Preclinical | $104M | 2 |
| IRD | Opus Genetics | Ophthalmology Rare | 5 | Approved | $391M | 12 |
| ORIC | Oric Pharmaceuticals | Oncology | 2 | Phase 3 | $831M | 5 |
| ORKA | Oruka Therapeutics | DermatologyImmunology Rare | 2 | Phase 2 | $6.53B | 7 |
| OVID | Ovid Therapeutics | Neurology Rare | 2 | Phase 2 | $419M | 4 |
| PTN | Palatin Technologies | ImmunologyMetabolic+1 | 1 | Phase 3 | $9.5M | 5 |
| PALI | Palisade Bio | Immunology | 1 | Phase 2 | $181M | 3 |
| KTTA | Pasithea Therapeutics | NeurologyOncology Rare | 2 | Phase 1 | $16.0M | 4 |
| CATX | Perspective Therapeutics | Oncology | 1 | Phase 1 | $104M | 5 |
| PHIO | Phio Pharmaceuticals | Oncology | 1 | Phase 1 | $8.6M | 4 |
| PYPD | PolyPid | Infectious DiseaseMetabolic+1 | 3 | NDA Submitted | $138M | 4 |
| DTIL | Precision Biosciences | Infectious DiseaseMetabolic+1 Rare | 1 | Phase 1 | $197M | 5 |
| PRME | Prime Medicine | GI/HepatologyRespiratory Rare | 1 | Phase 1 | $699M | 3 |
| PCSA | Processa Pharmaceuticals | GI/HepatologyImmunology+2 Rare | 1 | Phase 2 | $4.8M | 7 |
| PMN | ProMIS Neurosciences | Neurology Rare | 8 | Phase 1 | $28.9M | 9 |
| PRQR | ProQR Therapeutics | MetabolicNeurology Rare | 3 | Phase 1 | $163M | 7 |
| PTGX | Protagonist Therapeutics | DermatologyHematology+2 Rare | 5 | Approved | $8.14B | 12 |
| QTTB | Q32 Bio | Dermatology | 2 | Phase 2 | $258M | 3 |
| QNRX | Quoin Pharmaceuticals | DermatologyImmunology Rare | 2 | Phase 2 | $236M | 4 |
| RAPP | Rapport Therapeutics | Neurology | 3 | Phase 3 | $1.41B | 6 |
| RXRX | Recursion Pharmaceuticals | Oncology | 3 | Phase 2 | $1.69B | 6 |
| RLMD | Relmada Therapeutics | MetabolicNeurology+1 Rare | 1 | Phase 2 | $321M | 4 |
| RVPH | Reviva Pharmaceuticals | CardiovascularDermatology+3 Rare | 5 | Phase 3 | $4.7M | 11 |
| RVMD | Revolution Medicines | Oncology | 3 | Approved | $35.2B | 11 |
| RYTM | Rhythm Pharmaceuticals | Metabolic Rare | 1 | Approved | $8.08B | 14 |
| SANA | Sana Biotechnology | MetabolicOncology | 3 | Phase 1 | $563M | 4 |
| SRPT | Sarepta Therapeutics | NeurologyRespiratory Rare | 1 | Approved | $1.58B | 11 |
| SCYX | Scynexis | Infectious DiseaseRenal Rare | 1 | Approved | $28.4M | 5 |
| SLS | SELLAS Life Sciences Group | Oncology | 3 | Phase 3 | $3.90B | 9 |
| SEPN | Septerna | ImmunologyMetabolic+1 Rare | 2 | Phase 1 | $1.90B | 5 |
| SLDB | Solid Biosciences | CardiovascularNeurology Rare | 3 | Phase 3 | $695M | 6 |
| SPRB | Spruce Biosciences | Metabolic Rare | 1 | Preclinical | $116M | 2 |
| SYRE | Spyre Therapeutics | DermatologyImmunology Rare | 1 | Phase 2 | $8.91B | 10 |
| GPCR | Structure Therapeutics | MetabolicRespiratory Rare | 1 | Phase 3 | $3.90B | 5 |
| STRO | Sutro Biopharma | Oncology | 1 | Phase 1 | $148M | 3 |
| SNDX | Syndax Pharmaceuticals | ImmunologyOncology Rare | 3 | Approved | $822M | 7 |
| TSHA | Taysha Gene Therapies | Neurology Rare | 2 | Phase 3 | $1.30B | 4 |
| TLX | Telix Pharmaceuticals | Oncology | 6 | Approved | $3.01B | 25 |
| TLSA | Tiziana Life Sciences | ImmunologyNeurology Rare | 1 | Phase 2 | $83.2M | 5 |
| TVTX | Travere Therapeutics | MetabolicRenal Rare | 2 | Approved | $4.91B | 7 |
| TTRX | Turn Therapeutics | DermatologyInfectious Disease Rare | 2 | Phase 2 | $261M | 4 |
| RARE | Ultragenyx Pharmaceutical | CardiovascularMetabolic+1 Rare | 1 | Approved | $1.70B | 10 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | 1 | Approved | $230M | 27 |
| PCVX | Vaxcyte | Infectious Disease | 2 | Phase 3 | $9.40B | 7 |
| VERA | Vera Therapeutics | Infectious DiseaseRenal Rare | 1 | Approved | $1.89B | 6 |
| VIR | Vir Biotechnology | Infectious DiseaseOncology Rare | 1 | Phase 3 | $1.58B | 6 |
| VRDN | Viridian Therapeutics | ImmunologyOphthalmology | 3 | Approved | $3.41B | 7 |
| VYGR | Voyager Therapeutics | MetabolicNeurology Rare | 7 | Phase 1 | $94.6M | 9 |
| VTVT | vTv Therapeutics | HematologyMetabolic+1 Rare | 2 | Phase 3 | $69.4M | 9 |
| WVE | Wave Life Sciences | MetabolicNeurology+1 Rare | 1 | Phase 2 | $560M | 5 |
| XENE | Xenon Pharmaceuticals | Neurology Rare | 1 | NDA Submitted | $3.81B | 9 |
| ZBIO | Zenas BioPharma | DermatologyImmunology+2 Rare | 2 | NDA Submitted | $1.88B | 11 |
| ZYME | Zymeworks | OncologyRespiratory | 3 | Approved | $1.78B | 12 |
No companies match.